In pursuing the therapeutic mechanisms of AD 198, we found that it specifically targets c-Myc in TRAF3−/− mouse B lymphoma and human MM cells in dose-dependent and time-dependent manner [26]. This evidence concerns the gene MYC and Miyoshi myopathy.